Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a medical-device company’s disclosures is no small task, and Envoy Medical’s SEC filings add layers of clinical data, FDA correspondence, and nuanced revenue recognition to the usual financial statements. If you have ever sifted through hundreds of pages hunting for R&D burn rates or insider activity, you know the challenge behind Envoy Medical SEC filings explained simply.
Stock Titan solves that problem. Our AI reads every Envoy Medical quarterly earnings report 10-Q filing and annual report 10-K simplified, flags pivotal trial expenses, and turns dense footnotes into plain-English highlights. Real-time alerts land the moment an Envoy Medical Form 4 insider transactions real-time notice is posted, while side-by-side comparisons let you spot shifts in cash runway between quarters. Whether you are understanding Envoy Medical SEC documents with AI for the first time or need rapid Envoy Medical earnings report filing analysis, our platform keeps you current without drowning you in jargon.
Use the tools professionals rely on:
- Monitor Envoy Medical insider trading Form 4 transactions minutes after they hit EDGAR.
- Spot segment-level spending trends pulled from each Envoy Medical quarterly earnings report 10-Q filing.
- Track regulatory breakthroughs via Envoy Medical 8-K material events explained.
- Review pay-for-performance alignment inside the Envoy Medical proxy statement executive compensation sections.
- Stay ahead of catalysts with notifications on every Envoy Medical executive stock transactions Form 4.
From FDA milestone disclosures to liquidity analyses, Stock Titan’s AI surfaces what matters so you can act faster and smarter.
Alta Partners LLC filed a Schedule 13G reporting beneficial ownership of 1,944,139 shares of Envoy Medical, Inc. Class A common stock (shares issuable upon exercise of warrants), representing 8.25% of the class. Alta Partners reports sole voting and dispositive power over these shares and certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Envoy Medical (NASDAQ:COCH) announced the appointment of Robert Potashnick as Interim Chief Financial Officer, effective June 23, 2025. Potashnick, 45, will serve as the company's principal financial officer and principal accounting officer through his consulting entity Oasis Business Consulting LLC. He brings significant experience from previous CFO roles at Flutterbee Education Group and FOXO Technologies, along with positions at UnitedHealth Group and PricewaterhouseCoopers LLP. The appointment is structured through a Consulting Agreement on a fractional consultant basis.
FAQ
What is the current stock price of Envoy Medical (COCH)?
What is the market cap of Envoy Medical (COCH)?
